|
1
|
Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
|
Retina
|
2014
|
4.02
|
|
2
|
A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6.
|
Arch Ophthalmol
|
2009
|
3.46
|
|
3
|
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema.
|
Arch Ophthalmol
|
2009
|
2.84
|
|
4
|
Small-gauge pars plana vitrectomy: a report by the American Academy of Ophthalmology.
|
Ophthalmology
|
2010
|
1.32
|
|
5
|
SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion.
|
Ophthalmology
|
2009
|
1.30
|
|
6
|
Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
|
Ophthalmology
|
2012
|
1.23
|
|
7
|
The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials.
|
Am J Ophthalmol
|
2007
|
1.15
|
|
8
|
Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.
|
Arch Ophthalmol
|
2009
|
1.13
|
|
9
|
Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema.
|
Ophthalmology
|
2010
|
1.13
|
|
10
|
Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.
|
Ophthalmology
|
2011
|
1.09
|
|
11
|
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.
|
Ophthalmology
|
2011
|
1.06
|
|
12
|
The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4.
|
Arch Ophthalmol
|
2009
|
1.06
|
|
13
|
Optical coherence tomography findings in central retinal artery occlusion.
|
Ophthalmic Surg Lasers Imaging
|
2006
|
1.04
|
|
14
|
Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study.
|
Ophthalmology
|
2005
|
0.98
|
|
15
|
Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9.
|
Arch Ophthalmol
|
2010
|
0.96
|
|
16
|
SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design.
|
Am J Ophthalmol
|
2009
|
0.95
|
|
17
|
SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type.
|
Ophthalmology
|
2009
|
0.90
|
|
18
|
Score Study Report 12: Development of venous collaterals in the Score Study.
|
Retina
|
2013
|
0.90
|
|
19
|
Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism.
|
JAMA Ophthalmol
|
2013
|
0.87
|
|
20
|
Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology.
|
Ophthalmology
|
2012
|
0.83
|
|
21
|
Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14.
|
Arch Ophthalmol
|
2012
|
0.83
|
|
22
|
Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration.
|
Ophthalmic Surg Lasers Imaging Retina
|
2015
|
0.82
|
|
23
|
Retinal detachment due to an outer retinal tear following laser prophylaxis for retinoschisis.
|
Arch Ophthalmol
|
2008
|
0.81
|
|
24
|
Two discrete uveal melanomas in a child with ocular melanocytosis.
|
Retina
|
2006
|
0.80
|
|
25
|
It's time for a clinical trial to investigate intravitreal triamcinolone for macular edema due to retinal vein occlusion: the SCORE study.
|
Arch Ophthalmol
|
2005
|
0.79
|
|
26
|
Localized retinal manifestations of paraneoplastic autoimmune retinopathy.
|
Retin Cases Brief Rep
|
2014
|
0.79
|
|
27
|
Diabetic macular edema: therapeutic options.
|
Diabetes Ther
|
2012
|
0.78
|
|
28
|
Diabetic macular edema: a review of past, present, and future therapies.
|
Int Ophthalmol Clin
|
2004
|
0.77
|
|
29
|
Intravitreal triamcinolone for management of idiopathic juxtafoveolar telangiectasis.
|
Oman J Ophthalmol
|
2010
|
0.75
|
|
30
|
Reply.
|
Retina
|
2016
|
0.75
|
|
31
|
Reply: To PMID 24999721.
|
Retina
|
2015
|
0.75
|
|
32
|
Diagnostic and therapeutic challenges.
|
Retina
|
2010
|
0.75
|
|
33
|
SCORE Study Report 8: Closed Tests for All Pair-Wise Comparisons of Means.
|
Drug Inf J
|
2010
|
0.75
|
|
34
|
Diffuse macular edema in niacin-induced maculopathy may resolve with dosage decrease.
|
Retin Cases Brief Rep
|
2011
|
0.75
|
|
35
|
Subluxated/dislocated lens and hyphema as features of retinoblastoma.
|
Retina
|
2003
|
0.75
|